Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics with the potential to restore synapses that could improve the lives of patients worldwide, today ...

Schematic diagram (a) and photo (b) of the fabricated gas-filled hollow-core fiber phase modulator. (c) Measured loss spectrum and (d) transient response of the phase modulator. Credit: ...

This study demonstrates a compact optical modulation platform that enables real-time, high-resolution spectroscopy using sub-MHz interleaved combs generated via chip-scale acousto-optic phase ...

The design strategy for terahertz metasurfaces capable of achieving spin-selective functionality through complex-amplitude modulation is systematically categorized into four distinct parametric ...

A new technical paper titled “Hybrid tungsten oxyselenide/graphene electrodes for near-lossless 2D semiconductor phase modulators” was published by researchers at Nanyang Technological University, ...

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...

ADS051 is the first and only MRP2 / FPR1 inhibitor to demonstrate favorable safety and tolerability with signals of clinical efficacy with relief from disruptive symptoms of inflammatory bowel disease ...

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...